CytomX Therapeutics (CTMX)
CytomX Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
42.8M
Short interest
settlement 2026-10-15
13.8
Days to cover
+5.1 days vs prior
49.3%
Short share of volume
2026-11-02
10,347
Fails to deliver
settlement 2026-10-01
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CTMX is 42,790,446 shares, up 4,151,226 shares over the last month. Over the last 48 readings it ranged from 4,388,410 shares (29 November 2024) to 42,790,446 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 3.1M shares a day that is 13.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ctmx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 42,790,446 | +4.8% | 3,106,047 | 13.78 |
| 2026-09-30 | 40,813,393 | +5.6% | 4,704,960 | 8.67 |
| 2026-09-15 | 38,639,220 | +15.3% | 4,157,686 | 9.29 |
| 2026-08-31 | 33,512,293 | -3.2% | 2,837,694 | 11.81 |
| 2026-08-14 | 34,619,999 | -1.4% | 2,173,486 | 15.93 |
| 2026-07-31 | 35,110,952 | -12.9% | 2,981,073 | 11.78 |
| 2026-07-15 | 40,322,256 | +13.4% | 3,885,595 | 10.38 |
| 2026-06-30 | 35,567,462 | +16.2% | 8,231,326 | 4.32 |
| 2026-06-15 | 30,605,562 | +6.6% | 3,536,758 | 8.65 |
| 2026-05-29 | 28,719,341 | -7.8% | 3,085,637 | 9.31 |
| 2026-05-15 | 31,133,767 | +4.7% | 3,017,256 | 10.32 |
| 2026-04-30 | 29,742,798 | +8.1% | 3,523,518 | 8.44 |
| 2026-04-15 | 27,517,975 | +24.9% | 5,088,889 | 5.41 |
| 2026-03-31 | 22,031,153 | +7.9% | 19,392,256 | 1.14 |
| 2026-03-13 | 20,415,174 | +8.2% | 2,874,174 | 7.10 |
| 2026-02-27 | 18,864,576 | +11.2% | 2,348,345 | 8.03 |
| 2026-02-13 | 16,961,879 | +14.5% | 3,638,711 | 4.66 |
| 2026-01-30 | 14,813,750 | -8.1% | 4,443,328 | 3.33 |
| 2026-01-15 | 16,118,163 | -32.0% | 2,152,784 | 7.49 |
| 2025-12-31 | 23,696,755 | +41.3% | 3,610,233 | 6.56 |
| 2025-12-15 | 16,770,738 | -2.4% | 1,823,279 | 9.20 |
| 2025-11-28 | 17,187,962 | -41.4% | 2,255,989 | 7.62 |
| 2025-11-14 | 29,319,732 | +2.1% | 5,247,851 | 5.59 |
| 2025-10-31 | 28,725,162 | +1.1% | 2,371,627 | 12.11 |
| 2025-10-15 | 28,399,194 | -9.5% | 3,310,271 | 8.58 |
| 2025-09-30 | 31,366,190 | +8.3% | 5,632,695 | 5.57 |
| 2025-09-15 | 28,962,333 | +7.4% | 2,559,771 | 11.31 |
| 2025-08-29 | 26,968,192 | +7.3% | 2,967,263 | 9.09 |
| 2025-08-15 | 25,137,978 | +4.9% | 4,477,672 | 5.61 |
| 2025-07-31 | 23,959,184 | +0.4% | 1,295,784 | 18.49 |
| 2025-07-15 | 23,869,489 | +6.6% | 1,634,867 | 14.60 |
| 2025-06-30 | 22,393,569 | +7.7% | 2,933,159 | 7.63 |
| 2025-06-13 | 20,791,019 | +9.7% | 2,475,505 | 8.40 |
| 2025-05-30 | 18,961,903 | +7.0% | 4,352,781 | 4.36 |
| 2025-05-15 | 17,729,196 | +82.0% | 17,016,721 | 1.04 |
| 2025-04-30 | 9,743,354 | +1.8% | 1,399,255 | 6.96 |
| 2025-04-15 | 9,569,066 | +2.3% | 1,298,757 | 7.37 |
| 2025-03-31 | 9,355,778 | +3.9% | 1,040,631 | 8.99 |
| 2025-03-14 | 9,004,795 | +91.7% | 6,476,505 | 1.39 |
| 2025-02-28 | 4,696,740 | +6.7% | 622,327 | 7.55 |
| 2025-02-14 | 4,400,045 | -3.4% | 729,334 | 6.03 |
| 2025-01-31 | 4,552,893 | -1.7% | 739,805 | 6.15 |
| 2025-01-15 | 4,632,441 | -3.5% | 1,355,802 | 3.42 |
| 2024-12-31 | 4,798,768 | -13.4% | 1,084,209 | 4.43 |
| 2024-12-13 | 5,541,656 | +26.3% | 2,490,611 | 2.23 |
| 2024-11-29 | 4,388,410 | -1.1% | 778,988 | 5.63 |
| 2024-11-15 | 4,438,441 | -21.7% | 1,321,858 | 3.36 |
| 2024-10-31 | 5,666,225 | -6.6% | 753,693 | 7.52 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of CTMX volume is 49.3%, down 16.8 points over the last five sessions. Over the last 30 readings it ranged from 27.3% (22 October 2026) to 84.8% (22 September 2026). The latest reading is 14.7 points below the 30-session average of 64.0%, on 4.5M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 2.2M | 4.5M | 49.3% | 2,631 |
| 2026-10-30 | 1.3M | 1.7M | 74.5% | 0 |
| 2026-10-29 | 1.2M | 1.7M | 72.6% | 25 |
| 2026-10-28 | 743K | 1.4M | 51.9% | 0 |
| 2026-10-27 | 729K | 1.5M | 47.8% | 1,052 |
| 2026-10-26 | 1.5M | 2.3M | 66.1% | 0 |
| 2026-10-23 | 795K | 1.7M | 46.8% | 493 |
| 2026-10-22 | 327K | 1.2M | 27.3% | 0 |
| 2026-10-21 | 750K | 1.1M | 67.2% | 631 |
| 2026-10-20 | 976K | 1.4M | 70.4% | 300 |
| 2026-10-19 | 560K | 824K | 68.0% | 11,474 |
| 2026-10-16 | 817K | 1.2M | 68.5% | 2,182 |
| 2026-10-15 | 712K | 1.1M | 64.8% | 0 |
| 2026-10-14 | 845K | 1.3M | 62.7% | 32 |
| 2026-10-13 | 2.0M | 2.7M | 73.3% | 8,726 |
| 2026-10-12 | 643K | 877K | 73.3% | 0 |
| 2026-10-09 | 716K | 1.3M | 55.9% | 0 |
| 2026-10-08 | 915K | 1.3M | 69.6% | 300 |
| 2026-10-07 | 747K | 1.1M | 71.0% | 16 |
| 2026-10-06 | 494K | 706K | 69.9% | 0 |
| 2026-10-05 | 493K | 675K | 73.0% | 18 |
| 2026-10-02 | 619K | 1.0M | 59.1% | 4,700 |
| 2026-10-01 | 712K | 1.2M | 61.9% | 113 |
| 2026-09-30 | 695K | 1.3M | 54.7% | 0 |
| 2026-09-29 | 1.1M | 1.9M | 59.2% | 113 |
| 2026-09-28 | 687K | 978K | 70.3% | 0 |
| 2026-09-25 | 881K | 1.3M | 66.8% | 6,522 |
| 2026-09-24 | 737K | 1.2M | 59.7% | 0 |
| 2026-09-23 | 1.7M | 2.1M | 78.7% | 0 |
| 2026-09-22 | 3.6M | 4.2M | 84.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 1 October 2026, the fails-to-deliver balance in CTMX is 10,347 shares, down 125,618 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (10 July 2026) to 323,425 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-01 | 10,347 | $2.72 | $28K |
| 2026-09-10 | 135,965 | $3.54 | $481K |
| 2026-09-08 | 78 | $3.71 | $289 |
| 2026-08-18 | 608 | $3.45 | $2K |
| 2026-08-11 | 1,390 | $3.44 | $5K |
| 2026-08-04 | 1,940 | $3.17 | $6K |
| 2026-07-29 | 136 | $3.22 | $438 |
| 2026-07-24 | 581 | $3.33 | $2K |
| 2026-07-23 | 553 | $3.33 | $2K |
| 2026-07-21 | 309 | $3.52 | $1K |
| 2026-07-17 | 101 | $3.67 | $371 |
| 2026-07-14 | 2,958 | $3.70 | $11K |
| 2026-07-10 | 3 | $3.96 | $12 |
| 2026-07-09 | 4,313 | $3.83 | $17K |
| 2026-07-01 | 1,260 | $3.75 | $5K |
| 2026-06-30 | 323,422 | $3.74 | $1.2M |
| 2026-06-29 | 323,425 | $3.40 | $1.1M |
| 2026-06-23 | 50 | $3.04 | $152 |
| 2026-06-15 | 2,471 | $3.01 | $7K |
| 2026-06-10 | 129 | $2.98 | $384 |
| 2026-06-08 | 33,002 | $3.00 | $99K |
| 2026-05-29 | 411 | $3.71 | $2K |
| 2026-05-19 | 1,219 | $3.50 | $4K |
| 2026-05-18 | 7,600 | $3.61 | $27K |
| 2026-05-15 | 9,600 | $3.78 | $36K |
| 2026-05-13 | 6,142 | $3.88 | $24K |
| 2026-04-08 | 2,523 | $4.30 | $11K |
| 2026-03-23 | 22,142 | $4.45 | $99K |
| 2026-03-20 | 12,584 | $4.78 | $60K |
| 2026-03-19 | 62,636 | $4.40 | $276K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for CTMX in the last 90 days. The most recent filings are listed below. Latest filing: Carvajal Alejandra (Chief Legal Officer) on 2026-08-03.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | Carvajal Alejandra | Chief Legal Officer | Grant | 100K | $0.00 | $0 | 100K |
| 2026-06-15 | Ogden Christopher | Chief Financial Officer | Sell | 2K | $3.05 | $5K | 295K |
| 2026-03-17 | McCarthy Sean A. | CEO | Sell | 119K | $6.42 | $764K | 1.1M |
| 2026-03-17 | Ogden Christopher | Chief Financial Officer | Sell | 19K | $6.42 | $124K | 297K |
| 2026-03-17 | Chu Yu-Waye | Chief Medical Officer | Sell | 21K | $6.42 | $137K | 189K |
| 2026-03-17 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 31K | $6.42 | $202K | 301K |
| 2026-02-02 | Lester Rachael | Chief Business Officer | Grant | 20K | $0.00 | $0 | 20K |
| 2026-02-02 | Ogden Christopher | Chief Financial Officer | Grant | 90K | $0.00 | $0 | 316K |
| 2026-02-02 | McCarthy Sean A. | CEO | Grant | 210K | $0.00 | $0 | 1.2M |
| 2026-02-02 | Chu Yu-Waye | Chief Medical Officer | Grant | 75K | $0.00 | $0 | 211K |
| 2026-02-02 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant | 60K | $0.00 | $0 | 332K |
| 2025-11-06 | McCarthy Sean A. | CEO | Sell | 102K | $4.54 | $462K | 988K |
| 2025-06-16 | Ogden Christopher | Chief Financial Officer | Sell | 11K | $2.69 | $29K | 226K |
| 2025-06-16 | McCarthy Sean A. | CEO | Sell | 56K | $2.69 | $149K | 1.1M |
| 2025-06-16 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 14K | $2.69 | $37K | 272K |
| 2025-06-13 | Ogden Christopher | Chief Financial Officer | Exercise or conversion | 38K | $0.00 | $0 | 237K |
| 2025-06-13 | Ogden Christopher | Chief Financial Officer | Sell | 2K | $2.95 | $5K | 199K |
| 2025-06-13 | McCarthy Sean A. | CEO | Exercise or conversion | 150K | $0.00 | $0 | 1.1M |
| 2025-06-13 | BELVIN MARCIA | SVP, Chief Scientific Officer | Exercise or conversion | 38K | $0.00 | $0 | 286K |
| 2025-03-18 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 20K | $0.60 | $12K | 249K |
| 2025-03-18 | ROWLAND LLOYD A | General Counsel | Sell | 10K | $0.60 | $6K | 121K |
| 2025-03-18 | Chu Yu-Waye | Chief Medical Officer | Sell | 4K | $0.60 | $2K | 136K |
| 2025-03-18 | Ogden Christopher | Chief Financial Officer | Sell | 9K | $0.60 | $5K | 201K |
| 2025-03-18 | McCarthy Sean A. | CEO | Sell | 38K | $0.60 | $23K | 995K |
| 2025-02-04 | McCarthy Sean A. | CEO | Grant | 180K | $0.00 | $0 | 838K |
| 2025-02-04 | McCarthy Sean A. | CEO | Grant | 195K | $0.00 | $0 | 1.0M |
| 2025-02-04 | Ogden Christopher | Chief Financial Officer | Grant | 58K | $0.00 | $0 | 210K |
| 2025-02-04 | Ogden Christopher | Chief Financial Officer | Grant | 44K | $0.00 | $0 | 152K |
| 2025-02-04 | Chu Yu-Waye | Chief Medical Officer | Grant | 56K | $0.00 | $0 | 82K |
| 2025-02-04 | Chu Yu-Waye | Chief Medical Officer | Grant | 58K | $0.00 | $0 | 140K |
| 2025-02-04 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant | 58K | $0.00 | $0 | 263K |
| 2025-02-04 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant | 30K | $0.00 | $0 | 206K |
| 2025-02-04 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant | 35K | $0.00 | $0 | 211K |
| 2025-02-04 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant | 58K | $0.00 | $0 | 268K |
| 2024-08-20 | McCarthy Sean A. | CEO | Exercise or conversion | 38K | $0.00 | $0 | 672K |
| 2024-08-20 | McCarthy Sean A. | CEO | Sell | 14K | $1.23 | $17K | 658K |
| 2024-08-20 | Ogden Christopher | Chief Financial Officer | Sell | 2K | $1.23 | $2K | 108K |
| 2024-08-20 | Ogden Christopher | Chief Financial Officer | Exercise or conversion | 7K | $0.00 | $0 | 110K |
| 2024-08-20 | ROWLAND LLOYD A | General Counsel | Sell | 4K | $1.23 | $5K | 131K |
| 2024-08-20 | ROWLAND LLOYD A | General Counsel | Exercise or conversion | 11K | $0.00 | $0 | 135K |
| 2024-08-20 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 4K | $1.23 | $5K | 176K |
| 2024-08-20 | BELVIN MARCIA | SVP, Chief Scientific Officer | Exercise or conversion | 11K | $0.00 | $0 | 180K |
| 2024-08-20 | Landau Jeffrey B | Chief Business Officer | Sell | 4K | $1.23 | $5K | 119K |
| 2024-08-20 | Landau Jeffrey B | Chief Business Officer | Exercise or conversion | 11K | $0.00 | $0 | 123K |
| 2024-06-12 | Ogden Christopher | Chief Financial Officer | Grant | 18K | $0.00 | $0 | 103K |
| 2024-03-26 | McCarthy Sean A. | CEO | Exercise or conversion | 110K | $1.57 | $172K | 634K |
| 2024-03-19 | Landau Jeffrey B | Chief Business Officer | Sell | 7K | $2.09 | $14K | 110K |
| 2024-03-19 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 13K | $2.09 | $27K | 169K |
| 2024-03-19 | Ogden Christopher | SVP, Finance and Accounting | Sell | 3K | $2.09 | $6K | 86K |
| 2024-03-19 | McCarthy Sean A. | CEO | Sell | 20K | $2.09 | $42K | 524K |
| 2024-03-19 | ROWLAND LLOYD A | General Counsel | Sell | 5K | $2.09 | $11K | 118K |
| 2024-01-18 | Chu Yu-Waye | Chief Medical Officer | Grant | 26K | $0.00 | $0 | 26K |
| 2024-01-18 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant | 26K | $0.00 | $0 | 181K |
| 2024-01-18 | Landau Jeffrey B | Chief Business Officer | Grant | 30K | $0.00 | $0 | 117K |
| 2024-01-18 | Ogden Christopher | SVP, Finance and Accounting | Grant | 40K | $0.00 | $0 | 89K |
| 2024-01-18 | ROWLAND LLOYD A | General Counsel | Grant | 25K | $0.00 | $0 | 123K |
| 2024-01-18 | McCarthy Sean A. | CEO | Grant | 90K | $0.00 | $0 | 545K |
| 2023-12-20 | Ogden Christopher | SVP, Finance and Accounting | Sell | 2K | $1.38 | $3K | 49K |
| 2023-12-20 | ROWLAND LLOYD A | General Counsel | Sell | 4K | $1.38 | $6K | 98K |
| 2023-12-20 | Landau Jeffrey B | Chief Business Officer | Sell | 4K | $1.38 | $6K | 87K |
| 2023-12-20 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 4K | $1.38 | $6K | 155K |
| 2023-12-20 | McCarthy Sean A. | CEO | Sell | 14K | $1.38 | $19K | 455K |
| 2023-12-17 | BELVIN MARCIA | SVP, Chief Scientific Officer | Exercise or conversion | 11K | $0.00 | $0 | 159K |
| 2023-12-17 | ROWLAND LLOYD A | General Counsel | Exercise or conversion | 11K | $0.00 | $0 | 102K |
| 2023-12-17 | Landau Jeffrey B | Chief Business Officer | Exercise or conversion | 11K | $0.00 | $0 | 91K |
| 2023-12-17 | McCarthy Sean A. | CEO | Exercise or conversion | 38K | $0.00 | $0 | 468K |
| 2023-12-17 | Ogden Christopher | SVP, Finance and Accounting | Exercise or conversion | 7K | $0.00 | $0 | 51K |
| 2023-09-22 | ROWLAND LLOYD A | General Counsel | Sell | 5K | $1.30 | $7K | 81K |
| 2023-09-22 | McCarthy Sean A. | CEO | Sell | 15K | $1.30 | $19K | 431K |
| 2023-09-22 | Landau Jeffrey B | Chief Business Officer | Sell | 4K | $1.30 | $5K | 76K |
| 2023-09-22 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 4K | $1.30 | $5K | 148K |
| 2023-09-20 | ROWLAND LLOYD A | General Counsel | Grant | 15K | $0.00 | $0 | 86K |
| 2023-09-20 | McCarthy Sean A. | CEO | Grant | 40K | $0.00 | $0 | 445K |
| 2023-09-20 | Landau Jeffrey B | Chief Business Officer | Grant | 11K | $0.00 | $0 | 80K |
| 2023-09-20 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant | 11K | $0.00 | $0 | 152K |
| 2023-05-19 | McCarthy Sean A. | CEO | Exercise or conversion | 17K | $1.57 | $26K | 405K |
| 2023-03-29 | Jones Elaine V | Director | Buy | 5K | $1.55 | $8K | 5K |
| 2023-03-22 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant | 60K | $0.00 | $0 | 141K |
| 2023-03-16 | Peterson Amy C. | EVP, Chief Development Officer | Sell | 4K | $1.98 | $8K | 58K |
| 2023-03-16 | Landau Jeffrey B | Chief Financial Officer | Sell | 1K | $1.98 | $3K | 69K |
| 2023-03-16 | ROWLAND LLOYD A | General Counsel | Sell | 2K | $1.98 | $4K | 71K |
| 2023-03-16 | Campoy Carlos | Chief Financial Officer | Sell | 2K | $1.98 | $3K | 38K |
| 2023-03-16 | McCarthy Sean A. | CEO | Sell | 7K | $1.88 | $13K | 389K |
| 2023-03-16 | Ogden Christopher | SVP, Finance and Accounting | Sell | 516 | $1.98 | $1K | 38K |
| 2023-02-02 | Ogden Christopher | SVP, Finance and Accounting | Grant | 25K | $0.00 | $0 | 38K |
| 2023-02-02 | ROWLAND LLOYD A | General Counsel | Grant | 25K | $0.00 | $0 | 73K |
| 2023-02-02 | Landau Jeffrey B | Chief Business Officer | Grant | 40K | $0.00 | $0 | 71K |
| 2023-02-02 | McCarthy Sean A. | CEO | Grant | 105K | $0.00 | $0 | 396K |
| 2022-07-20 | Campoy Carlos | Chief Financial Officer | Sell | 4K | $1.42 | $6K | 40K |
| 2022-07-20 | HANNAH ALISON L. | Chief Medical Officer | Sell | 6K | $1.42 | $8K | 32K |
| 2022-07-20 | ROWLAND LLOYD A | General Counsel | Sell | 6K | $1.42 | $8K | 44K |
| 2022-07-20 | McCarthy Sean A. | President and CEO | Sell | 15K | $1.42 | $21K | 291K |
| 2022-07-20 | Landau Jeffrey B | Chief Business Officer | Sell | 4K | $1.42 | $6K | 31K |
| 2022-07-20 | Peterson Amy C. | EVP, Chief Development Officer | Sell | 7K | $1.42 | $11K | 63K |
| 2022-07-19 | Campoy Carlos | Chief Financial Officer | Grant | 15K | $0.00 | $0 | 44K |
| 2022-07-19 | HANNAH ALISON L. | Chief Medical Officer | Grant | 15K | $0.00 | $0 | 38K |
| 2022-07-19 | ROWLAND LLOYD A | General Counsel | Grant | 15K | $0.00 | $0 | 49K |
| 2022-07-19 | McCarthy Sean A. | President and CEO | Grant | 40K | $0.00 | $0 | 306K |
| 2022-07-19 | Landau Jeffrey B | Chief Business Officer | Grant | 11K | $0.00 | $0 | 35K |
| 2022-07-19 | Peterson Amy C. | EVP, Chief Development Officer | Grant | 20K | $0.00 | $0 | 70K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for CTMX worth $462K at the prices reported; 0 in the last 90 days worth $0. Latest: Sean McCarthy filed on 2025-11-06 to sell 101,793 shares ($462K) from 2025-11-06.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2025-11-06 | Sean McCarthyCEO | 102K | $462K | 0.062% | 2025-11-06 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON12 holders report 5% or more of CTMX in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 14.6% of the class (24,688,109 shares), filed 2026-02-05 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-28 | 13G/Ano. 1 | BANK OF AMERICA CORP /DE/parent holding company | 11.9M | 5.4% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 2 | Kynam Capital Management GP, LLCother entity | 0 | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Yue Tangindividual | 0 | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Kynam Capital Management, LPinvestment adviser | 0 | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Point72 Asset Management, L.P.partnership | 7.8M | 3.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Steven A. Cohenindividual | 7.8M | 3.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Point72 Capital Advisors, Inc.corporation | 7.8M | 3.6% | 2026-06-30 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 11.7M | 5.4% | 2026-06-30 |
| 2026-07-27 | 13G | BlackRock, Inc.parent holding company | 16.6M | 7.6% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 2 | VHCP Management III, LLCother entity | 10.0M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Bong Y. Kohindividual | 10.0M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Nimish Shahindividual | 10.0M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | VHCP Management EG, LLCother entity | 10.0M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Venrock Healthcare Capital Partners EG, L.P.partnership | 10.0M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | VHCP Co-Investment Holdings III, LLCother entity | 10.0M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Venrock Healthcare Capital Partners III, L.P.partnership | 10.0M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Patrick G. Enrightindividual | 15.3M | 7.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Juliet Tammenoms Bakkerindividual | 15.3M | 7.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Longitude Venture Partners V, L.P.partnership | 12.5M | 5.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Longitude Capital Partners V, LLCother entity | 12.5M | 5.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Longitude 103.8 East Partners, LLCother entity | 2.8M | 1.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Longitude 103.8 East, L.P.partnership | 2.8M | 1.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Perceptive Life Sciences Master Fund, Ltd.corporation | 10.1M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Joseph Edelmanindividual | 10.1M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Perceptive Advisors LLCinvestment adviser | 10.1M | 4.6% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Seven Fleet Capital Management LPother entity | 1.1M | 0.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Seven Fleet Master Fund LPpartnership | 1.1M | 0.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Brian Liuindividual | 1.1M | 0.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Seven Fleet Capital Management GP LLCother entity | 1.1M | 0.5% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 6 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 6 | TANG CAPITAL MANAGEMENT, LLCother entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 6 | KEVIN TANGindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 6 | TANG CAPITAL PARTNERS, LPpartnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 6 | TANG CAPITAL PARTNERS INTERNATIONAL, LPpartnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 6 | TANG CAPITAL PARTNERS III, INCcorporation | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 6 | TANG CAPITAL PARTNERS IV, INCcorporation | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | OrbiMed Advisors LLCinvestment adviser | 3.5M | 2.1% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 3 | FMR LLCparent holding company | 24.7M | 14.6% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 3 | Abigail P. Johnsonindividual | 24.7M | 14.6% | 2025-12-31 |
13F holders
Tracked managers holding CTMX at their latest 13F. JSON5 of the 30 tracked managers held CTMX at their latest 13F, $62.9M in total at quarter-end prices. Point72 Asset Management is the largest at $29.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 7.8M | $29.3M | 0.03% | -64K |
| Two Sigma Investments | 2026-06-30 | 4.1M | $15.5M | 0.01% | +1.4M |
| Citadel Advisors | 2026-06-30 | 3.1M | $11.7M | 0.00% | -2.3M |
| Millennium Management | 2026-06-30 | 1.7M | $6.3M | 0.00% | -2.0M |
| AQR Capital Management | 2026-06-30 | 42K | $158K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
CytomX Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows CytomX Therapeutics (CTMX), SEC CIK 1501989, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-01.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2025-11-06.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-28.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-03.JSON and CSV
- Company record
- EDGAR filing index for CIK 1501989Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of CTMX is sold short?
42,790,446 shares were held short at the 2026-10-15 settlement, 13.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CTMX's daily short volume?
On 2026-11-02, 2,235,420 of the 4,536,508 CTMX shares reported to FINRA were sold short, 49.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CTMX have fails to deliver?
The SEC's latest file shows 10,347 CTMX shares failed to deliver at settlement 2026-10-01. Fails are reported per settlement date and published twice a month with a lag.
Are CTMX insiders buying or selling?
No open-market insider trades were reported for CTMX in the last 90 days. The most recent filings are listed below. Latest filing: Carvajal Alejandra (Chief Legal Officer) on 2026-08-03.
Have CTMX insiders filed to sell?
1 Form 144 notice on file for CTMX worth $462K at the prices reported; 0 in the last 90 days worth $0. Latest: Sean McCarthy filed on 2025-11-06 to sell 101,793 shares ($462K) from 2025-11-06.
Who owns 5% or more of CTMX?
12 holders report 5% or more of CTMX in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 14.6% of the class (24,688,109 shares), filed 2026-02-05 for an event on 2025-12-31.
Which tracked 13F managers own CTMX?
5 of the 30 tracked 13F managers held CTMX shares at their latest filing, $62.9M in all. The largest: Steve Cohen's Point72 Asset Management (7.8M shares, $29.3M), Two Sigma Investments (4.1M shares, $15.5M), Ken Griffin's Citadel Advisors (3.1M shares, $11.7M), Izzy Englander's Millennium Management (1.7M shares, $6.3M), Cliff Asness's AQR Capital Management (42K shares, $158K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.